Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lauren J. Maruca"'
Autor:
Ronald G. Stoller, William C. Zamboni, David M. Friedland, Sakkaraiappan Ramalingam, Robert P. Edwards, S. Strychor, Lauren J. Maruca, Ramesh K. Ramanathan, Beth A. Zamboni, Chandra P. Belani, Huali Wu
Publikováno v:
Clinical Pharmacology & Therapeutics. 86:519-526
S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a63282381c3996798885ce1b4ae3a7a
https://doi.org/10.1038/clpt.2009.141
https://doi.org/10.1038/clpt.2009.141
Autor:
Ramesh K. Ramanathan, Merrill J. Egorin, Lauren J. Maruca, William C. Zamboni, Robert A. Parise, Sharon Marsh, Sandra Strychor, Todd A. Davis, Howard L. McLeod, Laura L. Jung, Sridhar Mani, Cristi R. King, Douglas M. Potter
Publikováno v:
Investigational New Drugs. 24:393-401
Purpose: The source of the pharmacokinetic variability of 9-nitrocamptothecin (9NC) and its 9-aminocamptothecin (9AC) metabolite is unknown. ATP-binding cassette (ABC) transporters have been reported to modulate camptothecin analogues, are associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0afd338ebdccd1c7e1f79bc4d09bbac
https://doi.org/10.1007/s10637-006-6335-5
https://doi.org/10.1007/s10637-006-6335-5
Autor:
Chandra P. Belani, Ronald G. Stoller, William C. Zamboni, Sandra Strychor, Huali Wu, Suresh Ramalingam, Beth A. Zamboni, David M. Friedland, Lauren J. Maruca, Yung Jue Bang, Robert P. Edwards, Ramesh K. Ramanathan
Publikováno v:
Journal of clinical pharmacology. 52(2)
S-CKD602 is a pegylated long-circulating liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. A population pharmacokinetic (PK) model for encapsulated and released CKD-602 following administration of S-CKD602 was developed to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ce94997049309b8e8a37aa681fc308
https://pubmed.ncbi.nlm.nih.gov/21233302
https://pubmed.ncbi.nlm.nih.gov/21233302
Autor:
Robert P. Edwards, Ronald G. Stoller, Yung Jue Bang, H-Y Lee, William C. Zamboni, David M. Friedland, Lauren J. Maruca, Sandra Strychor, Beth A. Zamboni, Chandra P. Belani, Ramesh K. Ramanathan, Suresh Ramalingam, J. K. Kim
Publikováno v:
Journal of liposome research. 21(2)
STEALTH(®) liposomal CKD-602 (S-CKD602), a camptothecin analog, is eliminated by the reticuloendothelial system (RES), which consists of cells, including monocytes. We evaluated the relationship between monocyte and absolute neutrophil counts (ANCs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a17b03282a760d586e175fd1edbcd434
https://pubmed.ncbi.nlm.nih.gov/20626314
https://pubmed.ncbi.nlm.nih.gov/20626314
Autor:
Ronald G. Stoller, Robert P. Edwards, Beth A. Zamboni, William C. Zamboni, Ramesh K. Ramanathan, David M. Friedland, Lauren J. Maruca, Suresh Ramalingam, Chandra P. Belani, Sandra Strychor
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(4)
Purpose: S-CKD602 is a pegylated liposomal formulation of CKD602, a semisynthetic camptothecin analogue. Pegylated (STEALTH) liposomes can achieve extended drug exposure in plasma and tumor. Based on promising preclinical data, the first phase I stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe3d9690c575c536d016839dc3bbbd2c
https://pubmed.ncbi.nlm.nih.gov/19190127
https://pubmed.ncbi.nlm.nih.gov/19190127
Autor:
Lauren J. Maruca, S. Strychor, Robert P. Edwards, Sakkaraiappan Ramalingam, Ramesh K. Ramanathan, Ronald G. Stoller, Beth A. Zamboni, David M. Friedland, Chandra P. Belani, William C. Zamboni
Publikováno v:
Journal of Clinical Oncology. 25:2528-2528
2528 Background: STEALTH liposomes (SL), which contain lipids conjugated to polyethylene glycol (PEG), prolong the circulation time of a drug in plasma, achieve high and extended drug exposure in tumor, and are eliminated via the reticuloendothelial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04be82c28f949bbe83677eb499c20df0
https://doi.org/10.1200/jco.2007.25.18_suppl.2528
https://doi.org/10.1200/jco.2007.25.18_suppl.2528
Autor:
Lauren J. Maruca, Y. J. Bang, H. P. Lee, Ramesh K. Ramanathan, Robert P. Edwards, S. Strychor, William C. Zamboni, J. K. Kim, Beth A. Zamboni, S.S. Ramalingam
Publikováno v:
Journal of Clinical Oncology. 25:2576-2576
2576 Background: STEALTH liposomal CKD-602 (S-CKD602), a camptothecin analogue, is eliminated by the reticuloendothelial system (RES), which consists of cells including monocytes. CKD-602 released from S-CKD602 is eliminated by the kidney. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d21091455ce5029e53ad93cf4f68c940
https://doi.org/10.1200/jco.2007.25.18_suppl.2576
https://doi.org/10.1200/jco.2007.25.18_suppl.2576